Releases Details

Appointment of Executive VP of Bioprocessing

Sep 6, 2023
RNS Number : 5613L
MaxCyte, Inc.
06 September 2023




MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing




ROCKVILLE, MD, September 6, 2023 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023.


Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale.


"With his commercial background, strategic insight and demonstrated commitment to strong financial performance, Ali will be a great addition to our executive leadership team," said Doug Doerfler, President and CEO of MaxCyte. "Ali's diverse experience will help build upon the initial success we have had with the VLx in our early access program. With Ali's help, we look forward to expanded engagement with early access customers and developing new customer relationships to deliver a large-scale transfection solution that addresses the current bottlenecks in the cell bioprocessing market."


Mr. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Mr. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario's Faculty of Engineering in Canada.


"As someone who understands the needs and expectations of life science customers, one of my goals is to develop and create new and innovative products and services that will continue to build MaxCyte's brand," said Mr. Soleymannezhad, EVP of Bioprocessing. "By executing a compelling marketing strategy that aligns with the Company's organizational objectives."



About MaxCyte 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at and follow us on Twitter and LinkedIn.


MaxCyte Contacts: 


US IR Adviser 

Gilmartin Group 

David Deuchler, CFA 

+1 415-937-5400  


US Media Relations 

Spectrum Seismic Collaborative 

Valerie Enes 

+1 408-497-8568 


Nominated Adviser and Joint Corporate Broker 

Panmure Gordon 

Emma Earl / Freddy Crossley 

Corporate Broking 

Rupert Dearden 

+44 (0)20 7886 2500 


UK IR Adviser 

Consilium Strategic Communications 

Mary-Jane Elliott 

Chris Welsh 

+44 (0)203 709 5700 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.